Results of consolidative radiotherapy for relapsed diffuse B-cell lymphoma

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMAURO, Geovanne Pedro
dc.contributor.authorRIBEIRO NETO, Mario
dc.contributor.authorCARVALHO, Heloisa de Andrade
dc.date.accessioned2024-04-05T19:40:06Z
dc.date.available2024-04-05T19:40:06Z
dc.date.issued2023
dc.description.abstractBackground: Recurrent diffuse large B-cell lymphoma (DLBCL) is a disease with high mortality. The standard of care involves autologous stem-cell transplantation (ASCT), which is not always feasible. We investigated the impact of radiotherapy as part of the salvage treatment for patients with relapsed disease. Materials and methods: Retrospective study of patients with recurrent DLBCL after chemotherapy and consolidative radiotherapy at a single institution. All patients were included if radiation was part of the first treatment. Results: Of 359 patients assessed between 2010 and 2017, 65 (18.1%) presented a recurrence, but only 62 received further treatment and were included in the study. Mean overall survival was 18.6 months since diagnosis and progression-free survival after first progression (PFS2) was 7.7 months. Patients were divided into two groups according to whether they did (24.8%) or did not (75.8%) receive radiation as part of their salvage treatment. Patients that did not receive R-CHOP (rituximab plus cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone) in the first line were treated more with radiation in the second line (p = 0.02). Six patients with in-field relapse were re-irradiated. Only 4 patients received ASCT as part of their treatment for relapsed disease. There was no difference in outcomes. Conclusion: There is a place for radiotherapy in the treatment of relapsed DLBCL, particularly when patients do not receive ASCT. Radiotherapy is well-tolerated. More trials to assess the role of radiotherapy for these patients are needed.eng
dc.description.indexPubMed
dc.description.indexScopus
dc.description.indexDimensions
dc.description.indexWoS
dc.identifier.citationREPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, v.28, n.5, p.601-607, 2023
dc.identifier.doi10.5603/rpor.96866
dc.identifier.eissn2083-4640
dc.identifier.issn1507-1367
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/59222
dc.language.isoeng
dc.publisherVIA MEDICAeng
dc.relation.ispartofReports of Practical Oncology and Radiotherapy
dc.rightsrestrictedAccesseng
dc.rights.holderCopyright VIA MEDICAeng
dc.subjectnon-Hodgkin lymphomaeng
dc.subjectrefractory lymphomaeng
dc.subjectradiotherapyeng
dc.subject.otherinvolved-field radiotherapyeng
dc.subject.otherradiation-therapyeng
dc.subject.othertransplantationeng
dc.subject.otherchemotherapyeng
dc.subject.otherregimenseng
dc.subject.otherstageeng
dc.subject.otherchopeng
dc.subject.wosOncologyeng
dc.subject.wosRadiology, Nuclear Medicine & Medical Imagingeng
dc.titleResults of consolidative radiotherapy for relapsed diffuse B-cell lymphomaeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcGEOVANNE PEDRO MAURO
hcfmusp.contributor.author-fmusphcMARIO RIBEIRO NETO
hcfmusp.contributor.author-fmusphcHELOISA DE ANDRADE CARVALHO
hcfmusp.description.beginpage601
hcfmusp.description.endpage607
hcfmusp.description.issue5
hcfmusp.description.volume28
hcfmusp.origemWOS
hcfmusp.origem.dimensionspub.1164780644
hcfmusp.origem.pubmed38179283
hcfmusp.origem.scopus2-s2.0-85178262069
hcfmusp.origem.wosWOS:001162115600004
hcfmusp.publisher.cityGDANSKeng
hcfmusp.publisher.countryPOLANDeng
hcfmusp.relation.referenceBiswas T, 2010, INT J RADIAT ONCOL, V77, P79, DOI 10.1016/j.ijrobp.2009.04.036eng
hcfmusp.relation.referenceFan JQ, 2023, RADIOTHER ONCOL, V183, DOI 10.1016/j.radonc.2023.109580eng
hcfmusp.relation.referenceFigura NB, 2022, EXPERT REV HEMATOL, V15, P1023, DOI 10.1080/17474086.2022.2147919eng
hcfmusp.relation.referenceFISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404eng
hcfmusp.relation.referenceGisselbrecht C, 2010, J CLIN ONCOL, V28, P4184, DOI 10.1200/JCO.2010.28.1618eng
hcfmusp.relation.referenceJones G, 2022, ONCOLOGY-NY, V36, P718, DOI 10.46883/2022.25920980eng
hcfmusp.relation.referenceKrishnan A, 2005, BLOOD, V105, P874, DOI 10.1182/blood-2004-04-1532eng
hcfmusp.relation.referenceMedici CTM, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01589-1eng
hcfmusp.relation.referenceNg AK, 2018, INT J RADIAT ONCOL, V100, P652, DOI 10.1016/j.ijrobp.2017.12.005eng
hcfmusp.relation.referenceOehler-Jänne C, 2008, HEMATOL ONCOL, V26, P82, DOI 10.1002/hon.839eng
hcfmusp.relation.referencePersky DO, 2008, J CLIN ONCOL, V26, P2258, DOI 10.1200/JCO.2007.13.6929eng
hcfmusp.relation.referencePHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305eng
hcfmusp.relation.referenceSehn LH, 2015, BLOOD, V125, P22, DOI 10.1182/blood-2014-05-577189eng
hcfmusp.relation.referenceWirth A, 2019, INT J RADIAT ONCOL, V103, P1158, DOI 10.1016/j.ijrobp.2018.12.006eng
hcfmusp.relation.referenceYahalom J, 2005, EUR J HAEMATOL, V75, P90, DOI 10.1111/j.1600-0609.2005.00461.xeng
hcfmusp.relation.referenceYeboa DN, 2015, J RADIOL ONCOL, V4, P11, DOI 10.1007/s13566-015-0182-yeng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication7ff72ab3-7134-494a-a54e-2dd1ed5cf031
relation.isAuthorOfPublicationbcc29746-329d-472c-a5ee-79e96c2fa593
relation.isAuthorOfPublicationc6ade631-12bb-4159-b85e-093571ff5cc3
relation.isAuthorOfPublication.latestForDiscovery7ff72ab3-7134-494a-a54e-2dd1ed5cf031
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - HC/InRad